Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Harrison, CN
34  Ergebnisse:
Personensuche X
?
1

Ruxolitinib versus best available therapy for polycythemia ..:

Harrison, CN ; Nangalia, J ; Boucher, R...
doi:10.1200/JCO.22.01935.  , 2024
Link: https://doi.org/10.1200/..
 
?
2

Tamoxifen for the treatment of myeloproliferative neoplasms..:

Fang, Z ; Corbizi Fattori, G ; McKerrell, T...
doi:10.1038/s41467-023-43175-5.  , 2024
Link: https://doi.org/10.1038/..
 
?
3

RAS-pathway mutations are common in patients with ruxolitin..:

O'Sullivan, JM ; Taylor, J ; Gerds, A...
doi:10.1038/s41375-023-02027-3.  , 2024
Link: https://doi.org/10.1038/..
 
?
4

Symptomatic benefit of momelotinib in patients with myelofi..:

Mesa, RA ; Hudgens, S ; Floden, L...
doi:10.1002/cam4.5799.  , 2024
Link: https://doi.org/10.1002/..
 
?
5

Ruxolitinib Versus Best Available Therapy for Polycythemia ..:

Harrison, CN ; Nangalia, J ; Boucher, R...
Journal of Clinical Oncology, 2023, pp. JCO2201935 -.  , 2023
Link: https://repository.icr.a..
 
?
6

Tamoxifen for the treatment of myeloproliferative neoplasms..:

Fang, Z ; Corbizi Fattori, G ; McKerrell, T...
https://discovery.ucl.ac.uk/id/eprint/10184486/1/Tamoxifen%20for%20the%20treatment%20of%20myeloproliferative%20neoplasms%20A%20Phase%20II%20clinical%20trial%20and%20exploratory%20analysis.pdf.  , 2023
Link: https://discovery.ucl.ac..
 
?
7

Different niches for stem cells carrying the same oncogenic..:

Grockowiak, E ; Korn, C ; Rak, J...
doi:10.1038/s43018-023-00607-x.  , 2023
Link: https://doi.org/10.1038/..
 
?
8

Continuous Indexing of Fibrosis (CIF): improving the assess..:

Harrington, H ; Ryou, H ; Sirinukunwattana, K...
doi:10.1038/s41375-022-01773-0.  , 2022
Link: https://doi.org/10.1038/..
 
?
9

Determining the recommended dose of pacritinib: results fro..:

Gerds, AT ; Savona, MR ; Scott, BL...
doi:10.1182/bloodadvances.2020003314.  , 2021
Link: https://doi.org/10.1182/..
 
?
10

Evaluating the Safety, Efficacy, and Therapeutic Potential ..:

Bassiony S ; Harrison CN ; McLornan DP
https://www.dovepress.com/evaluating-the-safety-efficacy-and-therapeutic-potential-of-momelotini-peer-reviewed-article-TCRM.  , 2020
Link: https://doaj.org/article..
 
?
11

The poor outcome in high molecular risk, hydroxycarbamide-r..:

O'Sullivan, JM ; Hamblin, A ; Yap, C...
doi:10.1182/blood.2019001861.  , 2020
Link: https://doi.org/10.1182/..
 
?
12

EXPAND, a dose-finding study of ruxolitinib in patients wit..:

Vannucchi, AM ; te Boekhorst, Peter ; Harrison, CN...
Vannucchi , AM , te Boekhorst , P , Harrison , CN , He , GS , Caramella , M , Niederwieser , D , Boyer-Perrard , F , Duan , MH , Francillard , N , Molloy , B , Wroclawska , M & Gisslinger , H 2019 , ' EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis ' , Haematologica , vol. 104 , no. 5 , pp. 947-954 . https://doi.org/10.3324/haematol.2018.204602.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
13

EXPAND, a dose-finding study of ruxolitinib in patients wit..:

Vannucchi, AM ; Boekhorst, P.A.W. (Peter) te ; Harrison, CN...
http://repub.eur.nl/pub/116826.  , 2018
Link: http://repub.eur.nl/pub/..
 
?
14

Treatment and management of myelofibrosis in the era of JAK..:

Keohane C ; Radia DH ; Harrison CN
http://www.dovepress.com/corrigendum-treatment-and-management-of-myelofibrosis-in-the-era--a14840.  , 2013
Link: https://doaj.org/article..
 
?
15

Treatment and management of myelofibrosis in the era of JAK..:

Keohane C ; Radia DH ; Harrison CN
http://www.dovepress.com/treatment-and-management-of-myelofibrosis-in-the-era-of-jak-inhibitors-a14104.  , 2013
Link: https://doaj.org/article..
 
1-15